Combined data from two phase III trials of the NK1 antagonist aprepitant plus a 5HT3 antagonist and a corticosteroid for prevention of chemotherapy-induced nausea and vomiting: effect of gender on treatment response
収録刊行物
-
- Supportive Care in Cancer
-
Supportive Care in Cancer 14 (4), 354-360, 2006-02-01
Springer Science and Business Media LLC